JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

17.59 -0.79

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.59

Max

17.66

Pagrindiniai rodikliai
By Trading Economics
Pajamos	6M
Pardavimai	162M
P/E Sektoriaus vid.	88.7 38.156
Pelno marža	3.676
Darbuotojai	1,811
EBITDA	-5M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+21.24% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3B
Ankstesnė atidarymo kaina	18.38
Ankstesnė uždarymo kaina	17.59

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

14.24 / 14.78 Palaikymas ir pasipriešinimas

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-25 17:53; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

2025-07-25 15:58; UTC

Uždarbis

Pagrindinės rinkos jėgos

Aon Shares Rise After 2Q Earnings Beat

2025-07-25 15:08; UTC

Pagrindinės rinkos jėgos

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

2025-07-25 21:40; UTC

Rinkos pokalbiai

Starbucks' Spending Hikes Are Misdirected -- Market Talk

2025-07-25 21:23; UTC

Rinkos pokalbiai

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

2025-07-25 20:40; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 20:10; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 19:56; UTC

Uždarbis

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

2025-07-25 19:14; UTC

Rinkos pokalbiai

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

2025-07-25 19:10; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

2025-07-25 19:01; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 18:45; UTC

Rinkos pokalbiai

Gold Ends Down Week on Lower Note -- Market Talk

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Sale Could Fetch Around $1B, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH in Talks to Sell Marc Jacobs -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

2025-07-25 17:38; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

2025-07-25 17:26; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Extends Decline -- Market Talk

2025-07-25 17:13; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 16:46; UTC

Uždarbis

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

2025-07-25 16:45; UTC

Uždarbis

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

2025-07-25 16:27; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-25 16:02; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

2025-07-25 15:34; UTC

Uždarbis

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

2025-07-25 15:06; UTC

Rinkos pokalbiai

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

2025-07-25 15:05; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

2025-07-25 14:45; UTC

Rinkos pokalbiai

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

2025-07-25 14:44; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

2025-07-25 14:36; UTC

Rinkos pokalbiai

Uždarbis

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

21.24% į viršų

12 mėnesių prognozė

Vidutinis 21.35 USD 21.24%

Aukščiausias 28 USD

Žemiausias 14.7 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.